Showing results (51-60 of 66) with videos related to
Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|April 18, 2026
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lungHirotsugu Kenmotsu, Seiji Niho, Masahiro Tsuboi, et al.Lung Cancer (Amsterdam, Netherlands)|June 6, 2025
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysisToshiya Fujisaki, Eisaku Miyauchi, Gen Kida, et al.International Journal of Clinical Oncology|October 13, 2021
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.Journal of Cachexia, Sarcopenia and Muscle|October 1, 2024
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050AKeita Miura, Takehito Shukuya, Naoki Furuya, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2025
A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)Hiroaki Akamatsu, Shinya Sakata, Koichi Azuma, et al.Lung Cancer (Amsterdam, Netherlands)|July 19, 2024
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, et al.Nature Communications|February 25, 2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancerHayato Mizuta, Koutaroh Okada, Mitsugu Araki, et al.The Lancet. Oncology|April 13, 2019
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, et al.The Lancet. Respiratory Medicine|August 29, 2021
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trialYosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, et al.Ebiomedicine|July 7, 2020
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 studyTatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, et al.Pageof 7